



PRESS RELEASE

Elizabeth Corsi and Julia Levy join Trillium Therapeutics' Board of Directors

Toronto, Canada – July 15, 2003 - Trillium Therapeutics Inc. (TTI) announced today that Drs. Elizabeth Corsi and Julia Levy have been appointed to the Company's Board of Directors. They join Drs. Calvin Stiller (Chairman), Luc Marengère, Brian Underdown, Gary Levy and Niclas Stiernholm (CEO).

"I am very pleased to welcome Drs. Levy and Corsi to the TTI board", commented Chairman, Dr. Calvin Stiller. "The board and the management are looking forward to working with two such accomplished industry leaders."

Dr. Elizabeth Corsi is currently President, Chief Executive Officer and Director of EXIMIAS Pharmaceutical Corporation. Prior to joining EXIMIAS, she was Senior Vice President, US Operations for Dupont-Merck Pharmaceuticals with P&L responsibility for the US business. Dr. Corsi has also held various senior management positions with Rhone-Poulenc Rorer and Schering-Plough International. She began her pharmaceutical industry career at Lederle Laboratories where she spent nine years and held a series of positions with increasing responsibilities, including the senior department head for marketing and business development. Dr. Corsi is a registered pharmacist, and earned a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy/Science and an M.B.A. from Pace University. She has been the recipient of numerous achievement awards, including Distinguished Alumni at the University of Pittsburgh, School of Pharmacy.

Dr. Julia Levy has held several key positions at QLT Inc., including President and CEO from 1995 to February 2002. Under Dr. Levy's leadership, QLT recorded the strongest period of growth in company history and earned a reputation for achieving milestones, including FDA approval for Visudyne® therapy to treat age-related blindness in April 2000. She currently serves as Executive Chairman of QLT Inc.'s Scientific Advisory Board. Dr. Levy has earned numerous awards and honors including the Order of Canada (2002), the Friesen-Rygiel Prize for medical

July 15, 2003

research and the Prix Galien Canada Research Award (2002). She received her Ph.D. in Immunology from the University of London and has published a large number of scientific articles.

“We are delighted to add such breadth of industry experience to the board, and believe that this is central to the company's future success”, added Dr. Luc Marengère, General Partner at VenGrowth Capital Management Inc., TTI's largest shareholder

TTI, a privately held Research and Development (R&D) company, specializes in the development of innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, graft rejection and viral hepatitis. The Company identifies therapeutic candidates with promising preclinical profiles and advances these into clinical testing, with the primary objective of demonstrating safety and efficacy in humans. The Company has two lead development candidates, a CD200 fusion protein (CD200Fc) and an Fgl2-specific monoclonal antibody (Fgl2 Mab). TTI has a variety of external R&D collaborations, including several with major pharmaceutical and biotechnology companies.

- 30 -

For further information, please contact:

Niclas Stiernholm, Ph.D.
Chief Executive Officer
Trillium Therapeutics Inc.
700 Bay Street, Suite 2108
Toronto, Ontario, M5G 1Z6
Canada

Tel: (416) 595-0627
Fax: (416) 595-5835
niclas@trilliumtherapeutics.com
www.trilliumtherapeutics.com